Special Issue "RNA Vaccines"
A special issue of Vaccines (ISSN 2076-393X).
Deadline for manuscript submissions: closed (31 July 2019) | Viewed by 61040
Interests: neglected tropical diseases; vaccines; adjuvants; parasitic diseases; helminths; protozoa; product development; hookworm; schistosomiasis; Chagas disease; Leishmaniasis
Interests: neglected tropical diseases; vaccine development; human pathogens; host-parasite interactions; immunology; flow cytometry; immunoassay development; innovation in research; soil transmitted helminths; Chagas disease; Chikungunya
Interests: neglected tropical diseases; vaccines; diagnostics; drug development; Project development
Interests: neglected tropical diseases; vaccines; analytical development; quality control; vaccine development
2. Pharmacology Department, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia
Interests: neglected tropical diseases; vaccines; analytical development; quality control; vaccine development; antimicrobials; resistant bacteria; Chagas disease; Leishmaniasis, MERS
In today’s world, billions of people are at risk for infection from ancient and newly-emerging tropical infectious diseases. Vaccines have been shown to have an enormous impact on overcoming the global burden of diseases; however, because of both technologic limitations and economic realities, scarcely any new vaccines for these diseases have made successful transition from development into licensure. Therefore, the world remains burdened by high morbidity diseases, as well as underprepared for the next biological threat or pandemic.
Novel technologies, lowering the cost of goods and accelerating the process of vaccine development could help address these urgent problems. In this Special Issue, entitled “RNA Vaccines against Tropical and Emerging Infectious Diseases”, we will present a compilation of articles that will focus on the recent scientific and technical progress made in the field of mRNA vaccines targeting neglected and emerging tropical infectious diseases. We invite authors to share their knowledge and experience to highlight how mRNA technology can help to i) improve vaccine potency and safety, ii) accelerate vaccine development, and iii) lower the cost of research, development and manufacturing.
Dr. Jeroen Pollet
Mr. Leroy Versteeg
Dr. Ulrich Strych
Dr. Mohan-Vivekanandan Poongavanam
Dr. Mashal Almutairi
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Tropical diseases
- Infectious diseases
- Emerging Diseases
- mRNA vaccine
- mRNA technology
- Public health
- vaccine development